Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1

Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a signif...

Full description

Bibliographic Details
Main Authors: Yu Pan, Qinglin Fei, Ping Xiong, Jianyang Yang, Zheyang Zhang, Xianchao Lin, Minggui Pan, Fengchun Lu, Heguang Huang
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:OncoImmunology
Subjects:
c-myc
pd-l1
jq1
immunotherapy
pancreatic cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1581529

Internet

http://dx.doi.org/10.1080/2162402X.2019.1581529

Similar Items